Resources Repository
-
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Technology Assessment | Cost-Effectiveness Analysis | North America | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Health/Medicine -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Technology Assessment | Cost-Effectiveness Analysis | North America | Preferences/Values | Health Outcomes | Mathematical Models | Health Systems | Health/Medicine | Science/Technology | Europe -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Technology Assessment | Cost-Effectiveness Analysis | North America | Preferences/Values | Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
GuidelinesPublication 2014EPA Guidelines for Preparing Economic Analyses
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for …
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for assessing the impacts of environmental regulations and policies that has been extensively peer-reviewed and is widely-applied both within and outside of the agency. The Guidelines discuss: (1) statutory and executive order requirements for conducting economic analyses; (2) identifying the need for policy action; (3) regulatory and non-regulatory approaches to pollution control; (4) baseline definition; (5) discounting future benefits and costs;…
Benefit-Cost Analysis | Decision Analysis | North America | Preferences/Values | Priority Setting/Ethics | Environmental Health | Policy/Regulation | Climate/Environment | Government/Law | Critical Thinking/Analysis -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | North America | Preferences/Values | Infectious Diseases | Policy/Regulation | Government/Law -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Technology Assessment | North America | Evidence Synthesis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | North America | Preferences/Values | Costing Methods | Chronic Disease/Risk | Mental Health | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
GuidelinesPublication 2017Guidelines for Regulatory Impact Analysis: A Primer
This “Frequently Asked Question” style document gives a brief overview of Regulatory Impact Analysis (RIA), …
This “Frequently Asked Question” style document gives a brief overview of Regulatory Impact Analysis (RIA), a method used by the US government to assess the consequences of proposed policies and their alternatives. The document is aimed at those who are new to the topic. RIAs apply a framework for collecting, organizing, and evaluating data. They help ensure that regulatory actions are justified and necessary to achieve social goals, and that these actions are implemented in the…
Benefit-Cost Analysis | North America | Business/Industry | Government/Law -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Decision Analysis | North America | Health Outcomes | Evidence Synthesis | Mathematical Models | Health Systems | Policy/Regulation | Health/Medicine